Biocon - Global Healthcare Company
 
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biosimilars & Fermentation
Oral Insulin & Immunosuppresants
  Biocon - Annual Report 2011
  Press Releases
  Concall Invite Q3 & 9M FY12
  Q3_9M FY12 Financial Results
  Branded Formulations
  Visit Abraxane
  Virtual Tour of Biocon
  Syngene-BMS Recruitments
     
 

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, we offer novel therapies on a platform of affordable innovation.

We believe our strategic licensing partnerships will rapidly provide us wider global access and greater market penetration. More significantly, they will enable us to deliver breakthrough therapeutics to millions of patients the world over.

 
     
INNOVATION WITHOUT ACCESS AND AFFORDABILITY IS LIKE THERAPY WITHOUT PATIENTS.
 
 

 
 
NEWS
 
Jan 11, Biocon Meets Clinical Trial Milestone for Psoriasis Drug...
Dec 22, Biocon in pact with US firm Pacific Biomarkers...
Dec 22, Clinigene partners US firm for speciality biomarkers...
Sept 11, Biocon to invest $161 million in Malaysia...
Aug 23, Clinigene partners US firm for clinical solutions...
 
 
 
 
Home  |  Contact Us  |  Site Map |  Biocon on:     Linked In 

BIOMAb e-CRF | Arogya Raksha Yojana | Biocon Foundation | ABLE | Karnataka Vision Group on Biotechnology | Karolinska Institute | Report Adverse Events/Side Effects and Products Complaints


 
  * Disclaimer | Authorised Users © 2011, Biocon. All Rights Reserved